Dopamine Is a Pathogenetic Factor in HIV-Induced Neuro-AIDS

  • Eleni Koutsilieri
  • Carsten Scheller
  • Stefanie Czub
  • Sieghart Sopper
  • Volker ter Meulen
  • Peter Riederer
Part of the Advances in Behavioral Biology book series (ABBI, volume 53)

Abstract

During the first years of the AIDS pandemic caused by the human immunodeficiency virus (HIV), a progressive, dementing illness, later called simply Neuro-AIDS, AIDS dementia complex or HIV dementia was defined as one of the consequences of the viral brain infection (Navia et al., 1986a; Navia et al., 1986b). According to WHO report, December 2000, it is estimated that around 36 million people world wide are infected with HIV. One-third of them is expected to develop HIV-dementia. HIV is the leading cause of dementia in people less than 60 years of age (Janssen et al., 1992; McArthur et al., 1993).

Keywords

Human immunodefIciency Virus Human Immunodeficiency Virus Type Human immunodefIciency Virus Infection Simian Immunodeficiency Virus Infection Thioctic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berger, J. R. and Arendt, G., 2000, HIV dementia: the role of the basal ganglia and dopaminergic systems, J. Psychopharmacol. 14:214–221.PubMedCrossRefGoogle Scholar
  2. Czub, S., Koutsilieri, E., Sopper, S., Czub, M., Stahl-Hennig, C., Müller, J. G., Pedersen, V., Gsell, W., Heeney, J. L., Gerlach, M., Gosztonyi, G., Riederer, P., and ter Meulen, V., 2001, Enhancement of CNS pathology in early simian immunodeficiency virus infection by dopaminergic drugs, Acta Neuropathol. 101:85–91.PubMedGoogle Scholar
  3. Dana Consortium, 1998, A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders, Neurology 50:645–651.CrossRefGoogle Scholar
  4. Gabby, M., Tauber, M., Porat, S., and Simantov, R., 1996, Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis, Neuropharmacology 35:571–578.PubMedCrossRefGoogle Scholar
  5. Itoh, K., Mehraein, P., and Weis, S., 2000, Neuronal damage of the substantia nigra in HIV-1 infected brains, Acta Neuropathol. 99:376–384.PubMedCrossRefGoogle Scholar
  6. Janssen, R. S., Nwanyanwu, O. C., Selik, R. M., and Stehr-Green, J. K., 1992, Epidemiology of human immunodeficiency virus encephalopathy in the United States, Neurology 42:1472–1476.PubMedCrossRefGoogle Scholar
  7. Kieburtz, K. D., Epstein, L. G., Gelbard, H. A., and Greenamyre, J. T., 1991, Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications, Arch. Neurol. 48:1281–1284.PubMedCrossRefGoogle Scholar
  8. Koutsilieri, E., Gotz, M. E., Sopper, S., Sauer, U., Demuth, M., ter Meulen, V., and Riederer, P., 1997, Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro, J. Neurovirol. 3:342–349.PubMedCrossRefGoogle Scholar
  9. McArthur, J. C., Hoover, D. R., Bacellar, H., Miller, E. N., Cohen, B. A., Becker, J. T., Graham, N. M., McArthur, J. H., Seines, O. A., Jacobson, L. P. et al, 1993, Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study, Neurology 43:2245–2252.PubMedCrossRefGoogle Scholar
  10. Mirsattari, S. M., Power, C., and Nath, A., 1998, Parkinsonism with HIV infection, Mov. Diwd. l3:684–689.CrossRefGoogle Scholar
  11. Navia, B. A., Cho, E. S., Petito, C. K., and Price, R. W., 1986a, The AIDS dementia complex: H. Neuropathology, Ann. Neurol. 19:525–535.PubMedCrossRefGoogle Scholar
  12. Navia, B. A., Jordan, B. D., and Price, R. W., 1986b, The AIDS dementia complex: I. Clinical features, Ann. Neurol. 19:517–524.PubMedCrossRefGoogle Scholar
  13. Price, R. W., 1996, Neurological complications of HIV infection, Lancet 348:445–452.PubMedCrossRefGoogle Scholar
  14. Rohr, O., Sawaya, B. E., Lecestre, D., Aunis, D., and Schaeffer, E., 1999, Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-kappaB in cells of the immune system, Nucleic Acids Res. 27:3291–3299.PubMedCrossRefGoogle Scholar
  15. Serieller, C., Sopper, S., Jassoy, C., ter Meulen, V., Riederer, P., and Koutsilieri, E., 2000, Dopamine activates HIV in chronically infected T lymphoblasts, J. Neural Transm. 107:1483–1489.CrossRefGoogle Scholar
  16. Tatton, W. G. and Greenwood, C. E., 1991, Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism, J. Neurosci. Res. 30:666–672.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Eleni Koutsilieri
    • 1
  • Carsten Scheller
    • 1
  • Stefanie Czub
    • 2
  • Sieghart Sopper
    • 1
  • Volker ter Meulen
    • 1
  • Peter Riederer
    • 3
  1. 1.Institute for Virology and ImmunobiologyWürzburgGermany
  2. 2.Institute for PathologyWürzburgGermany
  3. 3.Dept. PsychiatryInstitute for Clinical NeurochemistryWürzburgGermany

Personalised recommendations